Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint

Dow Jones05:55

Longeveron initiated a process of exploring options to maximize shareholder value after a stem cell therapy to treat a heart condition in children failed to meet its primary endpoint in a Phase 2b trial.

The clinical-stage biotechnology company said Wednesday that laromestrocel did not meet the endpoint of improvement in right ventricular ejection fraction at month 12 for infants with hypoplastic left heart syndrome.

"The Company has initiated a process of optimizing cost containment and will explore all options with the goal of maximizing shareholder value," Longeveron said, adding that it plans to engage an investment bank as a strategic adviser and has begun implementing cash conservation measures.

The company said it continues to analyze exploratory clinical endpoints from the trial, including the result of zero deaths among patients who received the therapy compared to one death in the control group. It plans to meet with the Food and Drug Administration to determine a potential path forward for the HLHS indication.

Longeveron also plans to pursue funding sources and revenue opportunities for the drug in longevity and aging-related frailty based on results from a separate clinical trial.

Trading of Longeveron shares was halted due to pending news shortly before the company's announcement.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2668467936?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 05:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668467936","market":"fut","top_or_hot":-1,"title":"Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Longeveron initiated a process of exploring options to maximize shareholder value after a stem cell therapy to treat a heart condition in children failed to meet its primary endpoint in a Phase 2b trial. \n</p>\n<p>\n  The clinical-stage biotechnology company said Wednesday that laromestrocel did not meet the endpoint of improvement in right ventricular ejection fraction at month 12 for infants with hypoplastic left heart syndrome. \n</p>\n<p>\n  \"The Company has initiated a process of optimizing cost containment and will explore all options with the goal of maximizing shareholder value,\" Longeveron said, adding that it plans to engage an investment bank as a strategic adviser and has begun implementing cash conservation measures. \n</p>\n<p>\n  The company said it continues to analyze exploratory clinical endpoints from the trial, including the result of zero deaths among patients who received the therapy compared to one death in the control group. It plans to meet with the Food and Drug Administration to determine a potential path forward for the HLHS indication. \n</p>\n<p>\n  Longeveron also plans to pursue funding sources and revenue opportunities for the drug in longevity and aging-related frailty based on results from a separate clinical trial. \n</p>\n<p>\n  Trading of Longeveron shares was halted due to pending news shortly before the company's announcement. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-09-17 05:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Longeveron initiated a process of exploring options to maximize shareholder value after a stem cell therapy to treat a heart condition in children failed to meet its primary endpoint in a Phase 2b trial. \n</p>\n<p>\n  The clinical-stage biotechnology company said Wednesday that laromestrocel did not meet the endpoint of improvement in right ventricular ejection fraction at month 12 for infants with hypoplastic left heart syndrome. \n</p>\n<p>\n  \"The Company has initiated a process of optimizing cost containment and will explore all options with the goal of maximizing shareholder value,\" Longeveron said, adding that it plans to engage an investment bank as a strategic adviser and has begun implementing cash conservation measures. \n</p>\n<p>\n  The company said it continues to analyze exploratory clinical endpoints from the trial, including the result of zero deaths among patients who received the therapy compared to one death in the control group. It plans to meet with the Food and Drug Administration to determine a potential path forward for the HLHS indication. \n</p>\n<p>\n  Longeveron also plans to pursue funding sources and revenue opportunities for the drug in longevity and aging-related frailty based on results from a separate clinical trial. \n</p>\n<p>\n  Trading of Longeveron shares was halted due to pending news shortly before the company's announcement. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2668467936","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2668467936","pubTimestamp":1789595700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Longeveron initiated a process of exploring options to maximize shareholder value after a stem cell therapy to treat a heart condition in children failed to meet its primary endpoint in a Phase 2b tri","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LGVN":"Longeveron Inc"},"translate_title":"心脏病药物未能达到终点后，Longeveron 探索实现股东价值最大化的选择","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGVN":1.5},"content_text":"Longeveron initiated a process of exploring options to maximize shareholder value after a stem cell therapy to treat a heart condition in children failed to meet its primary endpoint in a Phase 2b trial. \n\n\n  The clinical-stage biotechnology company said Wednesday that laromestrocel did not meet the endpoint of improvement in right ventricular ejection fraction at month 12 for infants with hypoplastic left heart syndrome. \n\n\n  \"The Company has initiated a process of optimizing cost containment and will explore all options with the goal of maximizing shareholder value,\" Longeveron said, adding that it plans to engage an investment bank as a strategic adviser and has begun implementing cash conservation measures. \n\n\n  The company said it continues to analyze exploratory clinical endpoints from the trial, including the result of zero deaths among patients who received the therapy compared to one death in the control group. It plans to meet with the Food and Drug Administration to determine a potential path forward for the HLHS indication. \n\n\n  Longeveron also plans to pursue funding sources and revenue opportunities for the drug in longevity and aging-related frailty based on results from a separate clinical trial. \n\n\n  Trading of Longeveron shares was halted due to pending news shortly before the company's announcement.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2668467936","isCrawlerRequest":true}